Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Hypertension (HTN) is the single most prevalent risk factor for cardiovascular disease,
diabetes, obesity and metabolic syndrome. Despite advances in life style modification and
multi-drug therapies, 20-30% of all hypertensive patients remain resistant.
These individuals exhibit autonomic dysregulation due to elevated sympathetic activity and
norepinephrine spillover, and low parasympathetic activity. It is generally accepted that
this uncontrolled, resistant HTN is primarily "neurogenic" in origin, involving over activity
of the sympathetic nervous system that initiates and sustains HTN. Thus, a mechanism-based
breakthrough is imperative to develop novel strategies to prevent and perhaps eventually cure
neurogenic hypertension (NH).
This study is a double-blind, placebo-controlled, cross-over design to test the hypothesis
that minocycline treatment would produce antihypertensive effects in drug-resistant
neurogenic hypertensive individuals.